About Hyccin 2
Hyccin 2 (HYCC2) is a protein
from Homo sapiens identified by UniProt accession
Q8IXS8, 530 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | Hyccin 2 |
| UniProt accession | Q8IXS8 |
| Gene | HYCC2 |
| Organism | Homo sapiens |
| Length | 530 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (32)
Diseases linked to this target (Open Targets).
- chronic lymphocytic leukemia · score 0.25
- body height · score 0.12
- total blood protein measurement · score 0.09
- monocyte count · score 0.06
- rheumatoid arthritis · score 0.04
- serum alanine aminotransferase measurement · score 0.03
- mean corpuscular volume · score 0.03
- mean platelet volume · score 0.03
- mean reticulocyte volume · score 0.03
- red blood cell density measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IXS8-F1 | alphafold | PREDICTED | 67.99 | — |
Amino-acid sequence (530 residues)
MLGTDRCVVE EWLSEFKALP DTQITSYAAT LHRKKTLVPA LYKVIQDSNN ELLEPVCHQL FELYRSSEVR LKRFTLQFLP ELMWVYLRLT VSRDRQSNGC IEALLLGIYN LEIADKDGNN KVLSFTIPSL SKPSIYHEPS TIGSMALTEG ALCQHDLIRV VYSDLHPQRE TFTAQNRFEV LSFLMLCYNS AIVYMPASSY QSLCRMGSRV CVSGFPRQHE KHWKELCGRI VLDPEFMVQL LTGVYYAMYN GQWDLGQEVL DDIIYRAQLE LFSQPLLVAN AMKNSLPFDA PDSTQEGQKV LKVEVTPTVP RISRTAITTA SIRRHRWRRE GAEGVNGGEE SVNLNDADEG FSSGASLSSQ PIGTKPSSSS QRGSLRKVAT GRSAKDKETA SAIKSSESPR DSVVRKQYVQ QPTDLSVDSV ELTPMKKHLS LPAGQVVPKI NSLSLIRTAS ASSSKSFDYV NGSQASTSIG VGTEGGTNLA ANNANRYSTV SLQEDRLGQA GEGKELLSPG APLTKQSRSP SFNMQLISQV
Explore Hyccin 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets